ClinicalTrials.gg

Program

glumetinib

Also written as “Glumetinib”, “Gumarontinib Tablets” and “Glumetinib Tablets”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by 2 companies.

Furthest: phase 3, since Aug 7, 20198 company-led studies, 4 open or runningNext primary completion: Dec 25, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Haihe Biopharma51 open or runningphase 2since Aug 7, 2019Aug 7, 2017none ahead
CSPC Pharmaceutical Group33 open or runningphase 3since Feb 11, 2025Jul 18, 2024Dec 25, 2026phase 2 · NCT06525350

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2017First study: phase 1 study in Advanced Solid TumorNew to Haihe BiopharmaHaihe Biopharma · NCT03466268 · 56 enrolled · China
  2. Feb 9, 2018Phase 1 study in Advanced Solid TumorHaihe Biopharma · NCT03457532 · 177 enrolled · China
  3. Aug 7, 2019Phase 2 study in C-Met Exon 14 MutationHaihe Biopharma · NCT04270591 · 183 planned · United States, China, Japan
  4. Mar 29, 2020Phase 2 study in Negative T790M Mutation and Met AmplificationHaihe Biopharma · NCT04338243 · 70 enrolled · China
  5. Aug 17, 2022Phase 1 study in Healthy VolunteersHaihe Biopharma · NCT05507294 · 18 enrolled · China
  6. Jul 18, 2024CSPC Pharmaceutical Group's first study: phase 2 study in RecurrenceNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT06525350 · 256 planned
  7. Feb 11, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT06829459 · 350 planned · China
  8. Mar 27, 2025Phase 3 study in RecurrenceCSPC Pharmaceutical Group · NCT06908772 · 390 planned

Ahead

  1. Dec 25, 2026Primary completion: phase 2 study in RecurrenceCSPC Pharmaceutical Group · NCT06525350
  2. Feb 15, 2028Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungCSPC Pharmaceutical Group · NCT06829459
  3. Dec 31, 2028Primary completion: phase 3 study in RecurrenceCSPC Pharmaceutical Group · NCT06908772

TargetBeta

MET →read by rule
“An orally bioavailable, small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
telisotuzumab adizutecanAbbViephase 318
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
vebreltinibrulebeijing-pearl-biotechnology-limited-liability-companyphase 39
vilzemetkibSino Biopharmaceuticalphase 38
dalmelitinibHansoh Pharmaceutical Groupphase 37
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
SHR-1826Jiangsu HengRui Medicinephase 27
pamvatamigruleBetta Pharmaceuticalsphase 25

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06908772Recurrence3Not yet recruitingCSPC Pharmaceutical GroupDec 31, 2028390
NCT06829459Carcinoma, Non-Small-Cell Lung · China3RecruitingCSPC Pharmaceutical GroupFeb 15, 2028350
NCT06525350Recurrence2Not yet recruitingCSPC Pharmaceutical GroupDec 25, 2026256
NCT05507294Healthy Volunteers · China1CompletedHaihe BiopharmaMay 21, 202118
NCT04338243Negative T790M Mutation and Met Amplification · China2UNKNOWNHaihe BiopharmaDec 31, 202070
NCT04270591C-Met Exon 14 Mutation · United States, China, Japan2RecruitingHaihe BiopharmaOct 25, 2023183
NCT03457532Advanced Solid Tumor · China1CompletedHaihe BiopharmaSep 22, 2023177
NCT03466268Advanced Solid Tumor · China1CompletedHaihe BiopharmaJan 9, 202356

How it is read

Names in the registry

  • “Glumetinib”, 4 entries
  • “Gumarontinib Tablets”, 2 entries
  • “Glumetinib Tablets”, 1 entry
  • “Glumetinib tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.